GRAIL

Historical price data

GRAIL's mission is to alleviate the global burden of cancer through early detection. The company has achieved a leading position in the MCED space with its Galleri test, supported by a robust clinical program involving over 385,000 participants, including landmark trials like NHS-Galleri. Its strategy centers on generating definitive clinical evidence to drive widespread adoption, secure reimbursement, and integrate its test into routine clinical care for adults at elevated risk.

A proprietary multi-cancer early detection platform combining ultra-deep next-generation sequencing, genome-wide methylation analysis, and machine learning to identify cancer signals from cell-free DNA in blood.

GRAIL is the clinical leader in MCED but faces growing competition from companies like Exact Sciences, Guardant Health, and Freenome. Its key advantages are its extensive clinical evidence base, proprietary methylation platform, and first-mover experience, but competition will intensify on price, partnerships, and payer coverage.